Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Not Yet Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07196592Not ApplicableNot Yet RecruitingPrimary

Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI

NCT06868030Not Yet Recruiting

Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study

Showing all 2 trials

Research Network

Activity Timeline